Holger H H Erb
Overview
Explore the profile of Holger H H Erb including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
668
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Israel J, Marcelin L, Mehralivand S, Scholze J, Hofmann J, Stope M, et al.
Biol Direct
. 2024 Nov;
19(1):111.
PMID: 39529201
Introduction: Dysregulated androgen receptor (AR) activity is central to various diseases, particularly prostate cancer (PCa), in which it drives tumour initiation and progression. Consequently, antagonising AR activity via anti-androgens is...
2.
Honscheid P, Baretton G, Puhr M, Siciliano T, Israel J, Stope M, et al.
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273225
Cancer-associated fibroblast (CAF)s in the tumour microenvironment (TME) modulate the extracellular matrix, interact with cancer cells, and facilitate communication with infiltrating leukocytes, significantly contributing to cancer progression and therapeutic response....
3.
Erb H, Polishchuk N, Stasyk O, Kahya U, Weigel M, Dubrovska A
Cancers (Basel)
. 2024 Aug;
16(16).
PMID: 39199642
Glutamine (Gln) is a non-essential amino acid that is involved in the development and progression of several malignancies, including prostate cancer (PCa). While Gln is non-essential for non-malignant prostate epithelial...
4.
Brandt M, Vakhrusheva O, Hackl H, Daher T, Tagscherer K, Roth W, et al.
Am J Pathol
. 2024 Aug;
194(11):2150-2162.
PMID: 39168364
Resistance to antiandrogens and chemotherapy (Cx) limits therapeutic options for patients with metastatic hormone-sensitive (mHSPC) and metastatic castration-resistant (mCRPC) prostate cancer. In this context, up-regulation of the glucocorticoid receptor is...
5.
Israel J, Marcelin L, Thomas C, Szczyrbova E, Fuessel S, Puhr M, et al.
J Exp Clin Cancer Res
. 2024 Jul;
43(1):194.
PMID: 39014480
Continued exploration of the androgen receptor (AR) is crucial, as it plays pivotal roles in diverse diseases such as prostate cancer (PCa), serving as a significant therapeutic focus. Therefore, the...
6.
Erdmann K, Distler F, Grafe S, Kwe J, Erb H, Fuessel S, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001515
Serum prostate-specific antigen (PSA), its derivatives, and magnetic resonance tomography (MRI) lack sufficient specificity and sensitivity for the prediction of risk reclassification of prostate cancer (PCa) patients on active surveillance...
7.
Kuster J, Erb H, Ahrend H, Abazid A, Stope M
Anticancer Res
. 2024 Jun;
44(7):2815-2821.
PMID: 38925843
Background/aim: The cytoprotective heat shock protein 27 (HSP27) acts as a protein chaperone, antioxidant, and apoptosis regulator and is involved in cytoskeletal remodeling in prostate cancer. This study was designed...
8.
Beier A, Ebersbach C, Siciliano T, Scholze J, Hofmann J, Honscheid P, et al.
Oncogene
. 2024 May;
43(26):2038-2050.
PMID: 38750263
Docetaxel (DX) serves as a palliative treatment option for metastatic prostate cancer (PCa). Despite initial remission, acquired DX resistance is inevitable. The mechanisms behind DX resistance have not yet been...
9.
Menzel V, Richter E, Helke C, Burk B, Erb H, Leike S, et al.
J Cancer Res Clin Oncol
. 2024 Apr;
150(4):201.
PMID: 38630148
Purpose: We assessed factors that affect the utilization of sperm cryopreservation before 2021, when patients covered expenses, and the influence on quality of life. Methods: Between 2011 and 2021, testicular...
10.
Borkowetz A, Sommer U, Baretton G, Gruellich C, Burk B, Erb H, et al.
World J Urol
. 2024 Feb;
42(1):94.
PMID: 38386122
Purpose: Cabozantinib (CAB) as monotherapy or in combination with immune checkpoint inhibitors is used for systemic treatment of metastatic renal cell carcinoma (mRCC). However, little is known about predictors of...